MX2012012926A - Tratamiento de enfermedades autoinmunes. - Google Patents

Tratamiento de enfermedades autoinmunes.

Info

Publication number
MX2012012926A
MX2012012926A MX2012012926A MX2012012926A MX2012012926A MX 2012012926 A MX2012012926 A MX 2012012926A MX 2012012926 A MX2012012926 A MX 2012012926A MX 2012012926 A MX2012012926 A MX 2012012926A MX 2012012926 A MX2012012926 A MX 2012012926A
Authority
MX
Mexico
Prior art keywords
alkyl
alkoxy
halogen
phenyl
formula
Prior art date
Application number
MX2012012926A
Other languages
English (en)
Spanish (es)
Inventor
Peter Gergely
Erik Wallstroem
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42199281&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012012926(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2012012926A publication Critical patent/MX2012012926A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
    • C07C321/24—Thiols, sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
    • C07C321/28—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
    • C07C321/30—Sulfides having the sulfur atom of at least one thio group bound to two carbon atoms of six-membered aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2012012926A 2010-05-06 2011-05-05 Tratamiento de enfermedades autoinmunes. MX2012012926A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10162079 2010-05-06
PCT/EP2011/057203 WO2011138393A1 (en) 2010-05-06 2011-05-05 Treatment of autoimmune diseases

Publications (1)

Publication Number Publication Date
MX2012012926A true MX2012012926A (es) 2012-12-17

Family

ID=42199281

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012012926A MX2012012926A (es) 2010-05-06 2011-05-05 Tratamiento de enfermedades autoinmunes.

Country Status (24)

Country Link
US (1) US20130172297A1 (https=)
EP (1) EP2566470A1 (https=)
JP (1) JP2013530937A (https=)
KR (1) KR20130066630A (https=)
CN (1) CN102869353A (https=)
AU (1) AU2011249784B2 (https=)
BR (1) BR112012028190A2 (https=)
CA (1) CA2795394A1 (https=)
CL (1) CL2012003091A1 (https=)
CR (1) CR20120566A (https=)
CU (1) CU20120154A7 (https=)
EA (1) EA201201514A1 (https=)
EC (1) ECSP12012312A (https=)
IL (1) IL222690A0 (https=)
MA (1) MA34285B1 (https=)
MX (1) MX2012012926A (https=)
NZ (1) NZ603999A (https=)
PE (1) PE20130612A1 (https=)
PH (1) PH12012502418A1 (https=)
SG (1) SG185746A1 (https=)
TN (1) TN2012000509A1 (https=)
TW (1) TW201201814A (https=)
WO (1) WO2011138393A1 (https=)
ZA (1) ZA201207710B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI519539B (zh) * 2010-12-21 2016-02-01 Kyorin Seiyaku Kk Diphenyl sulfide derivatives and pharmaceuticals as an active ingredient thereof
US9289494B2 (en) 2013-11-20 2016-03-22 RestorTears, LLC Method of treating ocular disorders with compounds found in Harderian gland secretions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1431275B1 (en) * 2001-09-27 2010-04-07 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivative, addition salt thereof, and immunosuppressant
MXPA04002679A (es) * 2001-09-27 2004-07-30 Kyorin Seiyaku Kk Derivados de sulfuro de diarilo, sales de los mismos y agentes inmunosupresores que utilizan los mismos.
KR101003877B1 (ko) 2002-09-19 2010-12-30 교린 세이야꾸 가부시키 가이샤 아미노알코올 유도체와 그 부가염 및 면역 억제제
US7456157B2 (en) 2003-02-18 2008-11-25 Kyorin Pharmaceutical Co., Ltd. Aminophosphonic acid derivatives, addition salts thereof and S1P receptor modulators
JP4716996B2 (ja) * 2003-05-26 2011-07-06 武田薬品工業株式会社 スルホピロール
CN1874996B (zh) 2003-08-28 2011-05-18 诺瓦提斯公司 氨基丙醇衍生物
EP1723138B1 (en) * 2004-02-11 2010-07-14 Basilea Pharmaceutica AG Substituted benzimidazoles and their use for inducing apoptosis
WO2006041015A1 (ja) * 2004-10-12 2006-04-20 Kyorin Pharmaceutical Co., Ltd. アミノアルコール誘導体とその付加塩及び免疫抑制剤
GB0504544D0 (en) * 2005-03-04 2005-04-13 Novartis Ag Organic compounds
SI2295049T1 (sl) * 2005-09-09 2015-03-31 Novartis Ag Zdravljenje avtoimunskih bolezni

Also Published As

Publication number Publication date
CU20120154A7 (es) 2013-03-27
CR20120566A (es) 2013-01-09
PH12012502418A1 (en) 2018-03-21
SG185746A1 (en) 2013-01-30
BR112012028190A2 (pt) 2016-08-02
IL222690A0 (en) 2012-12-31
KR20130066630A (ko) 2013-06-20
ECSP12012312A (es) 2012-12-28
CA2795394A1 (en) 2011-11-10
NZ603999A (en) 2014-06-27
PE20130612A1 (es) 2013-06-06
TN2012000509A1 (en) 2014-04-01
US20130172297A1 (en) 2013-07-04
EA201201514A1 (ru) 2013-05-30
CN102869353A (zh) 2013-01-09
MA34285B1 (fr) 2013-06-01
AU2011249784B2 (en) 2014-03-06
WO2011138393A1 (en) 2011-11-10
AU2011249784A1 (en) 2012-12-20
JP2013530937A (ja) 2013-08-01
ZA201207710B (en) 2013-06-26
CL2012003091A1 (es) 2013-03-22
TW201201814A (en) 2012-01-16
EP2566470A1 (en) 2013-03-13

Similar Documents

Publication Publication Date Title
CR20130560A (es) Compuestos de bezotiazol y su uso farmacéutico
CO2017000399A2 (es) Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos
ECSP14028506A (es) Nucleósidos de espirooxetano de uracilo
CR10614A (es) Derivados heterociclicos fusionados y metodos de uso
UY32490A (es) Inhibidores de beta-secretasa
PE20190515A1 (es) Peptidos modificados de auristatina y conjugados anticuerpo-farmaco de los mismos
AR055076A1 (es) Derivados de1,1-dioxido de 1,4-benzotiazepina,procedimiento para prepararlos,composiciones farmaceuticas que los contienen y usos en terapeutica.
PE20141598A1 (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
PA8828201A1 (es) Compuestos triazina como inhibidores mtor y quinasa p13
AR087913A1 (es) Inhibidores sustituidos de n-[1-ciano-2-(fenil)etil]-2-azabiciclo[2,2,1]heptan-3-carboxamida de catepsina c
CR20140007A (es) N-(6-((2r, 3s)-3,4-dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio) pirimidin-4-il)-3-metilacetidina-1-sulfonamida como modulador del receptor de quimiocina
PE20151005A1 (es) Composicion farmaceutica recubierta que contiene regorafenib
AR083879A1 (es) Analogos de aminoglicosidos antibacterianos, metodos de preparacion y uso como agentes terapeuticos
MX2017016149A (es) Compuestos triciclicos y su uso como inhibidores de la fosfodiesterasa.
PE20121523A1 (es) Metodo de tratamiento
CL2016000816A1 (es) Forma de dosificación que comprende al compuesto (s)-3-(4-((4-morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona, una cantidad de 90 hasta 99,9 por ciento en peso del peso total de una mezcla de almidón y lactosa como portador o excipiente, y acido esteárico como lubricante; su uso en el tratamiento de cáncer y enfermedades autoinmunes, entre otras.
PE20141155A1 (es) Analogos del acido epoxi-eicosatrienoico y metodos para hacer y de uso del mismo
ECSP14007965A (es) Formulaciones de (+)-2-[1-(3-etoxi-4-metoxi-fenil)-2-metansulfonil-etil]-4-acetil aminoisoindolin-1, 3-diona
AR087470A1 (es) Derivados imidazolicos bifenilenicos y composiciones farmaceuticas que los contienen
BR112017020081A2 (pt) análogos deuterados de etifoxina, seus derivados e usos dos mesmos
GT201300322A (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
AR071721A1 (es) Derivados de piridil-prolinamida, composiciones farmaceuticas que los contienen y su uso para el tratamiento de ansiedad, depresion y trastornos del sueno.
ECSP13012548A (es) Inhibidores de oxadiazol de la producción de leucotrienos.
MX2012012926A (es) Tratamiento de enfermedades autoinmunes.
CO6300937A2 (es) Derivados de 3-carboxipropil-aminotetralina y compuestos relacionados como antagonistas de receptores opioides mu

Legal Events

Date Code Title Description
FA Abandonment or withdrawal